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Abstract
Background: Registration of clinical trials has been introduced largely to reduce bias toward statistically significant
results in the trial literature. Doubts remain about whether advance registration alone is an adequate measure to reduce
selective publication, selective outcome reporting, and biased design. One of the first areas of medicine in which
registration was widely adopted was oncology, although the bulk of registered oncology trials remain unpublished. The
net influence of registration on the literature remains untested. This study compares the prevalence of favorable results
and conclusions among published reports of registered and unregistered randomized controlled trials of new oncology
drugs.
Methods: We conducted a cross-sectional study of published original research articles reporting clinical trials evaluating
the efficacy of drugs newly approved for antimalignancy indications by the United States Food and Drug Administration
(FDA) from 2000 through 2005. Drugs receiving first-time approval for indications in oncology were identified using the
FDA web site and Thomson Centerwatch. Relevant trial reports were identified using PubMed and the Cochrane Library.
Evidence of advance trial registration was obtained by a search of clinicaltrials.gov, WHO, ISRCTN, NCI-PDQ trial
databases and corporate trial registries, as well as articles themselves. Data on blinding, results for primary outcomes,
and author conclusions were extracted independently by two coders. Univariate and multivariate logistic regression
identified associations between favorable results and conclusions and independent variables including advance
registration, study design characteristics, and industry sponsorship.
Results: Of 137 original research reports from 115 distinct randomized trials assessing 25 newly approved drugs for
treating cancer, the 54 publications describing data from trials registered prior to publication were as likely to report
statistically significant efficacy results and reach conclusions favoring the test drug (for results, OR = 1.77; 95% CI = 0.87
to 3.61) as reports of trials not registered in advance. In multivariate analysis, reports of prior registered trials were again
as likely to favor the test drug (OR = 1.29; 95% CI = 0.54 to 3.08); large sample sizes and surrogate outcome measures
were statistically significant predictors of favorable efficacy results at p < 0.05. Subgroup analysis of the main reports from
each trial (n = 115) similarly indicated that registered trials were as likely to report results favoring the test drug as trials
not registered in advance (OR = 1.11; 95% CI = 0.44 to 2.80), and also that large trials and trials with nonstringent blinding
were significantly more likely to report results favoring the test drug.
Conclusions: Trial registration alone, without a requirement for full reporting of research results, does not appear to
reduce a bias toward results and conclusions favoring new drugs in the clinical trials literature. Our findings support the
inclusion of full results reporting in trial registers, as well as protocols to allow assessment of whether results have been
completely reported.
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Background
The clinical trial literature is known to be a biased source
of evidence on therapeutic efficacy. A number of potential
mechanisms accounting for bias have been identified [1].
Selective publication of "statistically significant" results
favoring new treatments is one well-established problem
[2-7]. Intrinsic factors of trial design can also lead to bias
in randomized controlled trials of drug efficacy [8,9]. Spe-
cific design features that have been associated with bias in
reported trials include blinding[8,10,11], sample size
[9,11-13], and choice of comparator [14-17]. Particular
data handling and analysis procedures have been associ-
ated with bias [13,18,19] and also incomplete reporting
of outcomes [2,20-22]. Trials and investigators supported
by pharmaceutical companies are more likely to report
results and conclusions favorable towards the sponsor's
product compared to placebo [13,14,23,24], or to the
drugs of other manufacturers [11,25], through mecha-
nisms that remain incompletely characterized.
The public registration of clinical trials has been intro-
duced, partly to satisfy ethical obligations of human
experimentation [26-30], and partly to reduce bias via sev-
eral mechanisms (increasing scrutiny of design, encourag-
ing publication, and encouraging full outcome reporting)
[7,31-33]. United States Federal law in 1997 mandated a
national registry http://www.clinicaltrials.gov, which was
operational by 1999 [30]. However the registry was at first
little used except in a few fields, notably oncology (where
it facilitated patient recruitment) [34]. Since the Interna-
tional Committee of Medical Journal Editors instituted a
policy requiring prior trial registration for publication in
cooperating journals from late 2005 [29], registration has
become much more common and may soon be a univer-
sal regulatory requirement [30,35]. However, doubts
remain about registration's adequacy in principle for pre-
venting bias due to trial design [36,37]. Furthermore,
there is evidence that registration alone may not greatly
influence biased outcome reporting: among registered tri-
als in cardiology, rheumatology, and gastroenterology
that have been published, many showed discrepancies
between primary outcomes as reported and outcomes as
registered, the vast majority of which tended to favor sta-
tistically significant results [37]. Similarly, advance regis-
tration of trials may not greatly discourage selective
publication: the majority of registered trials across all
fields remain unpublished, and are less likely to be pub-
lished if industry sponsored [38].
One of the main goals of trial registration is to reduce bias
in the literature through some combination of effects on
the mechanisms favoring new treatments. Oncology is
one field in which published results and conclusions have
been found to exhibit a bias favoring new drugs, associ-
ated statistically with drugmaker sponsorship and with
particular trial design features [39]. A minority of oncol-
ogy trials registered before September 2004 have reached
publication, indicating that the possibility of publication
bias in this field also remains [40]. In oncology, high
quality randomized clinical trials (those of the National
Cancer Institute's Cooperative Oncology Groups) have in
the long run favored new treatments very nearly as often
as comparator treatments, making this field unusually
advantageous for studying predictors of favorable out-
comes in that conditions approximately consistent with
equipoise have been demonstrated [41]. To assess
whether registration is associated with any net difference
in the prevalence of results and conclusions favoring new
drugs in the clinical trial literature, we conducted a cross-
sectional study of randomized clinical trial reports of
oncology drugs approved by the United States Food and
Drug Administration (FDA) from 2000 through 2005. We
hypothesized that advance trial registration is associated
with statistically non-significant efficacy outcomes in
published trial reports, when controlling for other known
predictors of reported results such as funding source, pub-
lication characteristics, and trial design characteristics.
Methods
Search strategy
We searched drug approvals by year on the FDA web site
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
index.cfm as well as Thomson CenterWatch http://
www.centerwatch.com/drug-information/fda-approvals/.
We identified 25 relevant drugs granted first-time FDA
approval for oncology indications in the 2000-2005
period, including both new molecular entities and older
drugs receiving new indications. We electronically
searched PubMed and the Cochrane Library in mid-Octo-
ber 2007 to identify reports of randomized controlled tri-
als including these drugs. Search terms were the generic
name(s) of the drugs of interest, in PubMed limited to
"randomized" or "randomised", "clinical trials", and
"humans". Our search included articles published in any
language. The search was updated in late February 2009 to
expand the sample so as to include reports published
through the end of 2008. Thus trial reports on all drugs of
interest were collected for a full nine-year interval sur-
rounding FDA approval, except for those drugs approved
in 2005, for which only eight years of literature was
searched.
Published Articles
We reviewed abstracts of all citations and retrieved articles
based on the following inclusion criteria: (1) prospective
randomized controlled trial; (2) oncology drug of interest
compared to a treatment arm not including that drug
(e.g., placebo or active control); (3) efficacy measured in
human cancer patients; (4) efficacy measured in terms of
direct effects on malignancy (not treatment-relatedTrials 2009, 10:116 http://www.trialsjournal.com/content/10/1/116
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pathology or supportive care only); (5) original research,
defined as studies that appeared to present original data
and did not specifically state that they were reviews. Stud-
ies with the primary objective of assessing the effect of the
oncology drug of interest combined with another treat-
ment were included, so long as one treatment arm includ-
ing the drug of interest was compared with an otherwise
identical arm lacking it, or with another treatment in its
place. In the case of oxaliplatin, approved in 2002 only in
combination with 5-fluorouracil and leucovorin, oxalipl-
atin was defined as the chief drug of interest and only tri-
als comparing the approved combination to a treatment
arm not containing oxaliplatin were included.
The following exclusion criteria were used to screen all
abstracts: (1) studies not evaluating clinical efficacy out-
comes (e.g., pharmacodynamic studies); (2) editorials,
letters-to-the-editor, commentaries, abstracts, reviews,
studies only describing a trial but not results; (3) studies
presenting only an economic analysis; (4) retrospective
analysis of outcome predictors not reporting any new effi-
cacy data; (5) studies in which the oncology drug of inter-
est was present in all arms of the trial; (6) studies
published more than four years before or after the year of
the oncology drug's approval in the 2000 to 2005 interval;
(7) studies presenting pooled data from multiple trials,
where individual trial results are not interpretable sepa-
rately; (8) studies in which the primary efficacy outcome
is not assessed statistically or not reported sufficiently for
statistical assessment; and (9) strictly biological or in vitro
analyses. We did not identify any exact duplicate publica-
tions. As we were interested in published trial reports, we
did include multiple publications from the same underly-
ing trial if the publications reported different data. Where
any doubt about a publication's eligibility for inclusion
remained after reading the abstract, it was provisionally
included for a full reading.
Data extraction
One investigator (N.R.) who was not blinded to author
names and affiliations, funding sources, and financial dis-
closure extracted all data from each article. All data were
extracted from articles before a search of the registration
status of the underlying trial was conducted. A second
coder (K.L.) who was blinded to registration status (except
where it was stated in the publication) independently
extracted data on blinding, identification and results of
primary outcomes, and author conclusions. Inter-rater
agreement was very good to excellent, with Kappa values
ranging from 0.85 to 0.95 for double-coded items. In
cases of disagreement the two coders discussed the papers
and reached agreement.
We extracted data on trial registration status and publica-
tion characteristics that have been shown to be independ-
ently related to publication of favorable results or
conclusions of drug studies, as follows [8-12,23].
Registration status
For all articles the registration status of the underlying trial
was sought by searching cancer type and drug names in
key databases. These included the U.S. National Institutes
of Health trial registry http://www.clinicaltrials.gov, the
International Standard Randomized Controlled Trial
Number Register http://isrctn.org, the WHO International
Clinical Trials Registry platform http://www.who.int/tri
alsearch/, the U.S. National Cancer Institute PDQ Com-
prehensive Cancer database http://www.cancer.gov/
Search/SearchClinicalTrialsAdvanced.aspx, and where
available, the corporate trial registries and databases of the
manufacturers of the drugs. Where the underlying trial
could unambiguously be identified in a registry or regis-
tries (by therapy protocols, inclusion criteria, patient
numbers, location, commencement date, etc.), the earliest
recorded date and place of registration was noted. For
analysis, only reports of trials registered in a year prior to
the earliest year of publication of results were classified as
registered. Some registered trial reports did not meet this
condition, as registration became a precondition of publi-
cation in many journals during the interval studied and
post-hoc registration was allowed to satisfy this require-
ment. Sixteen of the 83 papers coded as unregistered
appeared to have been registered in the same year as the
first report, thus presumably after trial completion.
Publication characteristics
Peer Review Status
Each article was classified as peer reviewed or non-peer
reviewed based on information found on the website of
the journal where the article was published. A publication
was considered peer reviewed if the website mentioned
that the journal had a peer review process or if it was
stated that the manuscripts were evaluated by at least one
external expert in the field; otherwise, a publication was
considered non-peer reviewed.
Impact Factor
For each article, impact factor for the journal in the year of
publication was obtained from the Institute for Scientific
Information [42].
Main report
Trial reports were classified as 1) first or main reports, if
they were the earliest article in a given drug's publication
sampling interval reporting results on a particular trial's
primary efficacy outcome measure in the full patient pop-
ulation, or 2) subsidiary reports if an earlier publication in
the sampling interval had disclosed results of the primary
outcome measure.Trials 2009, 10:116 http://www.trialsjournal.com/content/10/1/116
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Study design characteristics
Comparison group
The comparator for the primary outcome was classified as
1) placebo controlled, or 2) drug versus other treatment
only. In drug versus other treatment comparisons involv-
ing two different oncology drugs of interest, the "test"
drug was defined as the newer drug (most recent FDA
approval date) and the older drug as the "comparator".
If a trial included multiple treatment arms, the placebo
arm was treated as the comparator arm if present. If trials
included multiple arms differing in dosage of the oncol-
ogy drug of interest, the arm specifying the higher cumu-
lative dosage was treated as the "test" arm whenever
possible. If a publication reported results from multiple
trials, the trial with the largest number of patients rand-
omized was coded.
Equivalency or Superiority trial
Articles were classified as 1) equivalency/noninferiority
trial if stated in the publication or 2) superiority trial.
Type of primary outcome measures
The preferred efficacy outcome measure recommended by
the FDA for trials of antimalignancy therapies in this
period was overall survival [43]. We classified the primary
efficacy outcome reported in a publication as 1) overall
survival or an equivalent measure (e.g. time to death) or
2) surrogate, if a surrogate measure was specified as the
primary outcome. If no primary efficacy outcome was
stated, or more than one "primary" outcome, the most
emphasized efficacy outcome in the publication was des-
ignated the main outcome and treated as primary. In such
cases we operationalized "most emphasized" according to
word count in the results section, or if word count was
about equal, the outcome discussed first. Identification of
primary outcome measure was double-coded with high
agreement (although kappa cannot be calculated because
the number of possible outcome measures is indefinite).
Blinding
Blinding of treatment group allocation was classified on a
scale of 0 to 3 based on the scheme of Chalmers et al. [44],
with one point each for procedures assuring that patients
were unaware of their allocation, that treating physicians
and other patient care personnel were unaware, and that
those evaluating the primary efficacy endpoint were una-
ware. If papers stated only that they were "double blind"
without specifying procedures, they were classified with
only one point. For analysis, we dichotomized blinding
into "stringent" (score of 2 or 3) or "nonstringent" (score
of 0 or 1).
Sample Size
We recorded the total number of patients randomized to
all treatments as described in the article, or total number
enrolled if number randomized was not stated.
Statistical Significance of Primary Outcome
For each report, the results described for the primary effi-
cacy outcome were categorised as 1) favorable if the result
was statistically significant (p < 0.05 unless more stringent
criteria were specified) and in the direction of the test drug
being more efficacious, or 2) inconclusive if the result did
not reach statistical significance, or 3) unfavorable if the
result was statistically significant in the direction of the
comparator treatment being more efficacious. If a paper
explicitly stated that it was designed as a non-inferiority or
equivalency study and no significant efficacy difference
between the two comparison treatments was reported, the
result was coded as favorable. For analysis, conclusions
were dichotomised as favorable or not (combining incon-
clusive and unfavorable).
Conclusion
The overall conclusions reached in the published reports
were categorised as 1) favorable, if the test drug was pre-
ferred to comparator, 2) equivalent if the test drug was
described as about equal to comparator, or 3) unfavora-
ble, if the comparator was preferred to the test drug. If an
article did not clearly state that one of the treatments was
better or if the comparison treatments had different but
balanced advantages, the conclusion was coded as "test
drug equivalent to comparator". If a study explicitly stated
that it was designed as a non-inferiority or equivalency
trial and the comparison treatments were said to be about
equal, the conclusion was coded as favorable. For analy-
sis, conclusions were dichotomized as favorable or not
(combining equivalent and unfavorable).
Sponsorship information
Funding source
The funding source(s) of the published reports were cate-
gorized as 1) industry, 2) private non-profit, 3) govern-
ment, 4) other, 5) no funding, 6) none disclosed.
Financial ties
Data about the financial ties of each author were extracted
and coded for 1) whether or not there were ties of employ-
ment, research funding, consulting, stock ownership, or
honoraria disclosed with the sponsor of the study (yes,
no, or none disclosed), and 2) whether or not there were
these same financial ties disclosed with any other com-
pany (yes, no, or none disclosed).
For analysis these categories were collapsed into two
classes of sponsorship status, 1) sponsored by the test
drug maker, if such a funding source for the trial wasTrials 2009, 10:116 http://www.trialsjournal.com/content/10/1/116
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acknowledged explicitly, or where any author listed a rel-
evant corporate address or employment, and 2) not com-
mercially sponsored, if neither of the preceding categories
applied. Supply of materials, or consulting or honoraria
(etc.) on the part of authors did not in themselves qualify
as sponsorship. Only one study was sponsored by the
manufacturer of the comparator [45], and for analysis the
paper was recoded as if the comparator (in fact an even
newer drug) were the test drug.
Analysis
We report frequencies of the different characteristics of
each article by registration status of the trial. Proportions
of reports with favorable results or conclusions were first
analyzed using univariate logistic regression to identify
associations between independent variables and favora-
ble results and conclusions. Although impact factor and
sample size were continuous variables, they were mod-
eled categorically by quartile because their effects were
clearly non-linear. An exploration of interactions between
trial and publication characteristics revealed no interac-
tions except between trial sample size and journal impact
factor (see Results, below).
To control for multiple variables simultaneously, we car-
ried out multivariate logistic regression analysis and calcu-
lated odds ratios. These models included registration
status as our primary predictor and all factors statistically
associated either in the literature or in our univariate
models with favorable results or conclusions. The natural
log of sample size was treated as a numeric predictor. For
our primary analysis, we conducted the multivariate
regression on our full sample (n = 137). We carried out
pre-planned subgroup analyses of industry-sponsored
studies only (n = 109), and first or main reports only (i.e.,
one report per trial, n = 115). We also assessed sensitivity
of our results to our definition of registration by repeating
the primary multivariate analysis with both less stringent
definitions of advance trial registration (any evidence of
registration) and more stringent (evidence of registration
in a year at least two years prior to publication). Data were
analyzed with SAS software (version 9.1, SAS Institute,
Cary, NC, USA).
Results
As designed this study required a sample of 116 included
reports to achieve 80% power, assuming that 50% of
reports from registered trials would describe favorable
results and 75% from unregistered trials, and equal num-
bers of the two categories. Our actual full sample con-
sisted of 137 trial reports meeting inclusion criteria (see
Figure 1), and provided 85% power to distinguish the
expected proportions. The sample characteristics are
shown in Table 1. Thirty-nine percent (54/137) described
trials registered prior to the year of the first publication.
The majority of both registered and unregistered trial
reports were published in peer reviewed journals, did not
describe stringent blinding, reported on a surrogate pri-
mary efficacy outcome measure, and were sponsored by
the test drug maker. Fifty-eight percent (80/137) of the
trial reports described results that were statistically signif-
icant in favor of the test drug for the primary efficacy out-
come. Seventy-two percent (98/137) had conclusions that
favored the test drug.
Table 2 shows the results of univariate analysis of the full
sample. Reports of trials with large sample sizes were sig-
nificantly more likely to describe results and conclusions
favoring the test drug, as were reports published in higher
impact journals. Reports of trials sponsored by the maker
of a test drug were significantly more likely to reach con-
clusions favoring the drug than non-sponsored trial
reports. We found no statistically significant difference in
results or conclusions between registered and non-regis-
tered trial reports. Published reports of registered trials
were as likely to describe primary outcome results (OR =
1.77; 95% CI = 0.87 to 3.61) and conclusions (OR = 1.99;
95% CI = 0.89 to 4.45) favoring the test drug compared to
reports of non-registered trials.
In addition to registration status, we included industry
sponsorship and sample size in our multivariate analysis
because of their statistical significance in the univariate
analysis. We also included stringency of blinding, out-
come measure type, and comparator treatment type as
these trial characteristics had been associated with direc-
tion of results in similar studies [9,11,13,46]. Journal
impact factor was dropped from multivariate analysis
because interaction testing found that its correlation with
favorable results was accounted for by sample size. There
was no interaction between stringency of blinding and
surrogate outcome measure, or among any other varia-
bles. In the multivariate analysis (Table 3), reports of reg-
istered trials were again as likely to describe results
favoring the test drug (OR = 1.29; 95% CI = 0.54 to 3.08),
and to reach favorable conclusions (OR = 1.56; 95% CI =
0.60 to 4.05). Reports of trials with surrogate outcome
measures and large sample sizes (natural log) were signif-
icantly more likely to describe results favoring the test
drug (p = 0.027 and p < 0.001 respectively). Large sample
size was a significant predictor of conclusions favoring the
test drug (p = 0.006) in the multivariate analysis.
For the subset of trial reports sponsored by the test drug
makers (n = 109), results were essentially the same as for
the full set, reports of registered trials being as likely to
describe favorable results (OR = 1.37; 95% CI = 0.54 to
3.44). We also conducted a multivariate analysis for the
subgroup of first or main reports (n = 115), including
only one report per underlying trial (Table 4). As with theTrials 2009, 10:116 http://www.trialsjournal.com/content/10/1/116
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Table 1: Characteristics of included articles by registration status (n = 137)
Characteristic Prior registration
N = 54
No Prior Registration
N = 83
Publication characteristics
Peer reviewed 53 (98%) 76 (92%)
Year of publication
1996-2002 0 (0%) 29 (35%)
2003-2004 12 (22%) 28 (34%)
2005-2006 14 (26%) 19 (23%)
2007-2008 28 (52%) 7 (8%)
Impact factor, median (interquartile range)* 15.5 (10.9-34.8) 5.8 (4.0-10.5)
First or main report 45 (83%) 70 (84%)
Study design characteristics
Comparison group
Placebo 40 (74%) 32 (39%)
Active treatment only 14 (26%) 51 (62%)
Non-inferiority trial - Yes 2 (4%) 9 (11%)
Primary efficacy outcome = survival 21 (39%) 9 (11%)
Stringent blinding (2/3 points) 16 (30%) 20 (24%)
Sample size, median (interquartile range) 696 (150-923) 283 (99-565)
Statistical significance of primary outcome
Favorable to test drug 36 (67%) 44 (53%)
Inconclusive 18 (33%) 37 (45%)
Unfavorable 0 (%) 2 (2%)
Conclusion
Favorable to test drug 43 (80%) 55 (66%)
About equal 10 (18%) 22 (27%)
Unfavorable 1 (2%) 6 (7%)
Sponsored by test drug maker 47 (87%) 62 (75%)
*Only 127 articles were published in journals with a corresponding impact factor.Trials 2009, 10:116 http://www.trialsjournal.com/content/10/1/116
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full set of publications, we did not find a statistically sig-
nificant difference between registered and non-registered
trials in the reporting of favorable results or conclusions.
Published registered trials were as likely to report results
favoring the test drug (OR = 1.11; 95% CI = 0.44 to 2.80).
Results only differed from the full sample multivariate
analysis in that published trials with nonstringent blind-
ing were significantly more likely to report results favoring
the test drug (p = 0.028), whereas surrogate outcome
measure no longer reached significance as a predictor of
results, indicating that this latter trial characteristic was
over-represented among multiply-published trials.
A sensitivity analysis of our definition of prior registration
yielded qualitatively similar results for the different defi-
nitions. The more stringent definition of prior registration
(two years or more before first publication year) in our
multivariate model indicated that reports of registered tri-
als were at least as likely to describe favorable results (OR
= 1.58; 95% CI = 0.65 to 3.86) as compared with our basic
definition. The less stringent definition (any evidence of
registration) had an effect in the opposite direction (OR =
0.72; 95% CI = 0.30 to 1.72), suggesting that the timing of
trial registration may be a variable worthy of further study.
Discussion
We examined the association of trial registration and the
results and conclusions of published randomized control-
led trials of new oncology drugs. We found, contrary to
expectations, that published reports of pre-registered trials
were as likely to describe results favoring the test drug as
non-registered trials, even when controlling for other
Identification of trial reports for inclusion Figure 1
Identification of trial reports for inclusion.
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Table 2: Association between characteristics of articles and statistically significant results or conclusions that favor the test drug: 
Univariate logistic regression (n = 137).
Results Favor Test Drug Conclusions Favor Test Drug
Characteristic Category Favorable n/Total 
n (%)
OR
(95% CI)
P Favorable n/Total 
n (%)
OR
(95% CI)
P
Trial registration 
before publication
No 44/83 (53) 1.00 55/83 (66) 1.00
Yes 36/54 (67) 1.77 (0.87-3.61) 0.115 43/54 (80) 1.99 (0.89-4.45) 0.093
Year of publication 1996-2002 16/29 (55) 1.00 21/29 (72) 1.00
2003-2004 27/40 (68) 1.69 (0.63-4.53) 0.299 30/40 (75) 1.14 (0.39-3.38) 0.809
2005-2006 18/33 (55) 0.98 (0.36-2.66) 0.961 20/33 (61) 0.59 (0.20-1.71) 0.328
2007-2008 19/35 (54) 0.97 (0.36-2.59) 0.943 27/35 (77) 1.29 (0.41-4.00) 0.664
Impact Factor* Quartile 1 
(1.55-4.44)
15/32 (47) 1.00 19/32 (59) 1.00
Quartile 2 
(4.45-10.44)
19/33 (58) 1.54 (0.58-4.10) 0.389 22/33 (67) 1.37 (0.50-3.76) 0.543
Quartile 3 
(10.45-17.15)
20/35 (57) 1.51 (0.58-3.96) 0.402 26/35(74) 1.98 (0.70-5.57) 0.197
Quartile 4 
(17.16-52.59)
21/27 (78) 3.97 (1.27-12.43) 0.018 24/27 (89) 5.47 (1.36-22.01) 0.017
Blinding Stringent 18/36 (50) 1.00 25/36 (69) 1.00
Not stringent 62/101 (61) 1.59 (0.74-3.42) 0.236 73/101 (72) 1.15 (0.50-2.64) 0.747
Sample Size Quartile 1 (6-122) 10/34 (29) 1.00 19/34 (56) 1.00
Quartile 2 
(123-352)
22/34 (65) 4.40 (1.59-12.19) 0.004 24/34 (71) 1.90 (0.70-5.16) 0.211
Quartile 3 
(353-772)
22/35 (63) 4.06 (1.48-11.12) 0.006 26/35 (74) 2.28 (0.83-6.30) 0.112
Quartile 4 
(773-8010)
26/34 (76) 7.8 (2.64-23.03) <0.001 29/34 (85) 4.58 (1.43-14.69) 0.011
Primary efficacy 
outcome
Survival 17/30 (57) 1.00 21/30 (70) 1.00
Surrogate 63/107 (59) 1.10 (0.48-2.48) 0.828 77/107 (72) 1.10 (0.45-2.67) 0.833
Comparison group Active comparator 35/65 (54) 1.00 45/65 (69) 1.00
Placebo 45/72 (63) 0.70 (0.35-1.39) 0.306 53/72 (74) 0.81 (0.38-1.70) 0.571
Sponsored No 14/28 (50) 1.00 15/28 (54) 1.00
Yes 66/109 (61) 1.54 (0.67-3.54) 0.314 83/109 (76) 2.77 (1.17-6.56) 0.021
*Only 127 articles were published in journals with a corresponding impact factor.Trials 2009, 10:116 http://www.trialsjournal.com/content/10/1/116
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important predictors of statistical significance of results,
including trial sample size, blinding, and industry spon-
sorship. Reports of registered trials in our sample actually
appear more likely to favor new drugs (though not signif-
icantly); if so, one possible explanation is that trials
expected to reflect favorably on new drugs were registered
early.
Our findings argue for measures in addition to trial regis-
tration alone to ensure that statistically non-significant
results are fully reported. Public access to statistically non-
significant results is essential for conducting valid meta-
analysis, advancing science, and enabling clinical deci-
sions based on complete evidence [47-49]. Issues about
the quality, assessment and presentation of non-peer-
reviewed data in trial registers must be resolved, along
with commercial concerns, without undue delay [30,48].
However, given the evidence that particular trial design
features were associated with reported results, notwith-
standing registration, our findings also suggest that results
access through registries alone may never entirely elimi-
nate the bias favoring new drugs in the clinical trial litera-
ture.
It might be argued that many registered "negative" trials of
these recent oncology drugs have not yet been completed,
or not yet submitted for publication, or that they have
been rejected multiple times by journals. However, previ-
ous studies suggest that authors' decisions not to submit
manuscripts, rather than journal rejection, account for the
Table 3: Association between characteristics of articles and statistically significant outcome or conclusions that favor the test drug: 
Multivariate logistic regression (full sample, n = 137)
Results Favor Test Drug Conclusions Favor Test Drug
Characteristic Category Favorable n/Total 
n (%)
OR
(95% CI)
P Favorable n/Total 
n (%)
OR
(95% CI)
P
Trial registration 
before publication
No 44/83 (53) 1.00 55/83 (66) 1.00
Yes 36/54 (67) 1.29 (0.54-3.08) 0.566 43/54 (80) 1.56 (0.60-4.05) 0.363
Blinding Stringent 18/36 (50) 1.00 25/36 (69) 1.00
Not stringent 62/101 (61) 2.33 (0.95-5.76) 0.066 73/101 (72) 1.51 (0.59-3.91) 0.394
Sample Size Natural log - 2.28 (1.49-3.48) <0.001 - 1.77 (1.18-2.66) 0.006
Comparison group Active comparator 35/65 (54) 1.00 45/65 (69) 1.00
Placebo 45/72 (63) 2.06 (0.87-4.90) 0.101 53/72 (74) 1.47 (0.59-3.63) 0.410
Primary efficacy 
outcome
Survival 17/30 (57) 1.00 21/30 (70) 1.00
Surrogate 63/107 (59) 3.42 (1.15-10.14) 0.027 77/107 (72) 3.04 (0.95-9.68) 0.061
Sponsored No 14/28 (50) 1.00 15/28 (54) 1.00
Yes 66/109 (61) 1.01 (0.37-2.67) 0.999 83/109 (76) 2.01 (0.76-5.31) 0.157Trials 2009, 10:116 http://www.trialsjournal.com/content/10/1/116
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majority of unpublished studies with statistically insignif-
icant results [2,3,50,51]
Our study has several limitations. We focused on oncol-
ogy drugs because they were most likely to include a sam-
ple of registered trials. Thus, our findings may not be
generalizable to other classes of drugs. We were not able
to examine trials of drugs that were never approved by the
FDA as this list of drugs is not provided by the FDA. Our
study design did not allow us to assess trials that were not
published. In addition, to focus on trials of new therapies,
we excluded studies published more than four years
before or after the year of the oncology drug's approval in
the 2000-2005 interval. Since trials with positive results
are published significantly earlier than trials with negative
results (4.3 yrs vs 6.5 yrs, respectively) [4], we may have
failed to identify some studies yet to be published on the
more recently approved drugs. However, these latter two
limitations apply equally to prior registered and non-reg-
istered trials. We examined only the primary efficacy out-
comes of the trials, and thus cannot determine whether
trial registration might influence the reporting of second-
ary outcomes or safety outcomes. Lastly, trial registration
has become increasingly common. Thus, our cross-sec-
tional study offers only an early look at the effects of trial
registration on results and conclusions in a particular
sample of registered and unregistered trial reports. How-
ever, subsequent studies on the association of registration
with reported results will be constrained to a before/after
design and its attendant shortcomings.
Table 4: Association between characteristics of trials and statistically significant outcome or conclusions favoring the test drug: 
Multivariate logistic regression (first/main reports only, n = 115)
Results Favor Test Drug Conclusions Favor Test Drug
Characteristic Category Favorable n/Total 
n (%)
OR
(95% CI)
P Favorable n/Total 
n (%)
OR
(95% CI)
P
Trial registration 
before publication
No 34/70 (49) 1.00 46/70 (66) 1.00
Yes 28/45 (62) 1.11 (0.44-2.80) 0.832 34/45 (76) 1.10 (0.41-2.98) 0.854
Blinding Stringent 13/31 (42) 1.00 20/31 (65) 1.00
Not stringent 49/84 (58) 3.03 (1.13-8.16) 0.028 60/84 (71) 1.86 (0.69-5.05) 0.221
Sample size Natural log - 2.20 (1.40-3.45) <0.001 - 1.65 (1.09-2.51) 0.019
Comparison group Active comparator 24/51 (47) 1.00 33/51 (65) 1.00
Placebo 38/64 (59) 2.33 (0.89-6.07) 0.084 47/64 (73) 1.98 (0.73-5.41) 0.182
Primary efficacy 
outcome
Survival 14/25 (56) 1.00 17/25 (68) 1.00
Surrogate 48/90 (53) 2.76 (0.82-9.28) 0.102 63/90 (70) 2.86 (0.80-10.18) 0.105
Sponsored No 13/27 (48) 1.00 15/27 (56) 1.00
Yes 49/88 (56) 1.02 (0.37-2.84) 0.965 65/88 (74) 1.94 (0.71-5.29) 0.194Trials 2009, 10:116 http://www.trialsjournal.com/content/10/1/116
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Conclusions
Trial registration alone, without a requirement for full
reporting of research results, does not appear to reduce a
bias toward results and conclusions favoring new drugs in
the clinical trials literature. Our findings support the
inclusion of full results reporting in trial registers, as well
as measures to allow assessment of whether results have
been completely reported. However, bias related to study
design may remain. Possible policy solutions for design
bias include advance review of trial protocols, compliance
with existing reporting requirements, and adherence to
best research practices.
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